24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceuticals
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:10
Here’s how gaming brands can reach wider audiences: “Never make assumptions!”
09:01
Israel’s gaming sector is 2% of its GDP - so why is the government ignoring it?
08:59
“Israelis are trained in working and managing their businesses under extreme conditions”
08:39
TechAir flights from Israel to New York take off January 21
More stories
Buzz
Most popular
Daily
Weekly
1
Have missiles from the Iranian-backed Houthis discovered a loophole in Israeli air defenses?
2
Kaltura CEO: "Just like a missile hit our office, a missile hit us with the IPO"
3
Windward acquired for $270M by FTV Capital, doubling its IPO valuation
4
$41B in exits: Why Israeli cyber startups are a global powerhouse
5
8 Israeli cyber companies travel to the UK for collaboration opportunities
More news
Pharmaceuticals
20 stories about Pharmaceuticals
Entera Bio Files for Nasdaq IPO
12.11.17
|
Lilach Baumer
The clinical stage company develops treatments mostly for osteoporosis and bone disorders
Fitch Downgrades Teva to Junk Rating
07.11.17
|
Yaniv Rahimi
The U.S. credit agency changed Teva's rating from BBB to BB, with a negative outlook, due to "significant operational stress." The downgrade might affect Teva's ability to take on additional debt
There May Be a Silver Lining to Teva’s Woes
06.11.17
|
Eli Shimony
Analysts have lowered their target price for Teva following the company's less than stellar third quarter reports, but the company can still turn its luck around with new drugs and a willingness to tighten the belt
Allergan Planning Sale of its Teva Stock
01.11.17
|
Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
New CEO to Take Helm at Troubled Teva Wednesday
31.10.17
|
Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
Teva's Blockbuster Drug Takes Another Generic Blow
26.10.17
|
Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
Teva Canada Probed by Ontario Government
23.10.17
|
Lilach Baumer
According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.
Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm
19.10.17
|
Lilach Baumer
NeuroDerm is looking to bring major change to Parkinson patients with its drug reformulation
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
Teva Submits Potential Moneymaker Migraine Drug for FDA Approval
18.10.17
|
Dror Reich and Lilach Baumer
Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year
Lonza to Open Research and Development Center in Israel
10.10.17
|
Lilach Baumer
The company is looking to boost the research and development projects of its pharma and biotech division
Drug Conduction Company Prepares for Nasdaq IPO
08.10.17
|
Golan Hazani
Clinical stage PolyPid develops technology for the predetermined, controlled and localized release of drugs at a targeted site
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
Pharma Companies Arcturus Therapeutics and Alcobra to Merge
28.09.17
|
Lilach Baumer
The merged entity will develop treatments for infectious diseases, cystic fibrosis, and rare liver diseases
Automated Medical Diagnosis Startup Raises $30 Million
19.09.17
|
Omer Kabir
Israel-based MeMed develops an automated blood testing device that can distinguish between bacterial and viral infections. The company previously raised funds from the U.S. Department of Defense
Teva Sells Remaining Women's Health Assets
18.09.17
|
Lilach Baumer
After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal
Teva Negotiating Sale of Remaining Women's Health Assets, Report Says
14.09.17
|
Lilach Baumer
CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday
IPO Hopeful Entera Bio Moves to Better Position
13.09.17
|
Dror Reich
Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism
The Ten Challenges Facing Teva's New CEO
12.09.17
|
Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles
Please ensure Javascript is enabled for purposes of
website accessibility